The effects of brain radiotherapy combined with immunotherapy and chemotherapy for driver gene-negative non-small-cell lung cancer with brain metastases

1

This study included 222 driver gene-negative NSCLC patients with brain metastases to evaluate treatment efficacy.
2

Patients were divided into two groups: RT+CT+ICI (radiotherapy, chemotherapy, and immunotherapy) and RT+CT (radiotherapy and chemotherapy).
3

The median overall survival was significantly longer in the RT+CT+ICI group at 19.6 months compared to 15 months in the RT+CT group.
4

Stereotactic radiosurgery was identified as a protective factor for overall survival in these patients.
5

PD-L1 expression was associated with better progression-free survival and intracranial progression-free survival in driver gene-negative NSCLC patients.

Frontiers In Oncology

by Xiaoyu Zhang, Jiayi Huang, Xuan Liang, Zhiping Ruan, Yu Yao, Xiao Fu, Tao Tian
July 6, 2026

1